LumiThera Inc., based in Seattle, WA has reported positive results for a “LIGHTSITE II” study, (NCT NCT03878420) conducted by a multi-centre clinical trial in dry… Read More »LumiThera Inc., (Seattle, Washington) announces initial European data on photobiomodulation (PBT) results for treatment of dry AMD
AsciepiX Therapeutics Inc., based in Baltimore, Maryland, has announced that the first patient has been dosed in the Phase 1/2a “CONGO” clinical trial to evaluate… Read More »AsclepiX Therapeutics Inc. has reported the first dose of a novel peptide treatment in Phase 1/2a for Diabetic Macular Edema (DME)
Gemini Therapeutics (Nasdaq: GMTX), a US-based clinical stage ophthalmic company focused on age-related macular degeneration (AMD), has announced a Phase 2a treatment (“ReGAtta” study) and… Read More »Gemini Therapeutics (Cambridge, MA) expect to announce Phase 2a results in H12021 for dry AMD therapy.
A French surgical-robotics company in Montpellier, “AcuSurgical”, has announced a Series A funding of around €5.75 million for an advanced robotic microsurgical platform for the… Read More »“AcuSurgical”, a robotics company for retinal microsurgery based in Montpellier, France, has raised €5.75M funding.
A US biotechnology company, Advernum Biotechnologies Inc., (NASDAQ:ADVM), has announced the enrolment of a Phase 2 study for the treatment of diabetic macular edema (DME),… Read More »Advernum Biotechnologies Inc., (NASDAQ: ADVM) expects to enrol Phase 2 patients for a treatment for DME using the aflibercept gene.
A Dutch biotechnology company, ProQR Therapeutcis N.V., (NASDAQ:PRQR), Leiden, has announced the enrolment of a phase 2/3 study for the treatment of Leber Congenital Amaurosis… Read More »ProQR Therapeutics N.V. (NASDAQ: PRQR), expects to enrol 36 patients of LCA10 using a novel therapy for “Sepofarsen” (QR-110)
Genentech (a member of the Roche Group [SIX: RO, ROG; OTCQX: RHHBY]) have announced positive top-line results from two identically designed global Phase III studies,… Read More »Genentech (a subsidiary of Roche) has reported a key non-inferior end-point for faricimab for DME, gearing up for a head-to-head anti-VEGF market
A biotechnology company, Neurogene Inc., has raised $115 million in a second-round financing to be used to accelerate clinical trials. A range of treatments for… Read More »A biotechnology company founded by Neurogene Inc. (NY, USA) has raised $115M to focus on rare Batten disease.
Applied Genetic Technologies Corporation Inc. (Nasdaq: AGTC) has reported positive data from a Phase 1/2 clinical study for 28 X-linked retinitis pigmentosa (XLRP) patients. The company… Read More »Applied Genetic Technologies Corporation (NASDAQ: AGTC; Florida, USA) has reported positive data from a Phase 1/2 study for X-linked retinitis pigmentosa.
Novartis International AG (SIX: NOVN; NYSE: NVS) has announced the acquisition of Vedere Bio, a venture based optogenetics company in Cambridge, Massachusetts. Vedere had developed… Read More »Novartis AG has acquired optogenetics company Vedere Bio for a value up to $280M.